MRK Stock Overview
MERCK Kommanditgesellschaft auf Aktien operates in the healthcare, life science, and performance materials sectors worldwide.
MERCK Kommanditgesellschaft auf Aktien Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||€193.85|
|52 Week High||€231.50|
|52 Week Low||€126.60|
|1 Month Change||-11.81%|
|3 Month Change||-0.62%|
|1 Year Change||30.28%|
|3 Year Change||115.25%|
|5 Year Change||91.46%|
|Change since IPO||1,149.91%|
Recent News & Updates
Is MERCK Kommanditgesellschaft auf Aktien (ETR:MRK) A Risky Investment?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
We Think MERCK Kommanditgesellschaft auf Aktien (ETR:MRK) Can Manage Its Debt With Ease
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
A Look At The Intrinsic Value Of MERCK Kommanditgesellschaft auf Aktien (ETR:MRK)
In this article we are going to estimate the intrinsic value of MERCK Kommanditgesellschaft auf Aktien ( ETR:MRK ) by...
|MRK||DE Pharmaceuticals||DE Market|
Return vs Industry: MRK exceeded the German Pharmaceuticals industry which returned 16.3% over the past year.
Return vs Market: MRK exceeded the German Market which returned 12.1% over the past year.
|MRK Average Weekly Movement||4.2%|
|Pharmaceuticals Industry Average Movement||5.4%|
|Market Average Movement||5.0%|
|10% most volatile stocks in DE Market||9.8%|
|10% least volatile stocks in DE Market||2.6%|
Stable Share Price: MRK is not significantly more volatile than the rest of German stocks over the past 3 months, typically moving +/- 4% a week.
Volatility Over Time: MRK's weekly volatility (4%) has been stable over the past year.
About the Company
|1668||59,308||Belen Garijo Lopez||https://www.merckgroup.com|
MERCK Kommanditgesellschaft auf Aktien operates in the healthcare, life science, and performance materials sectors worldwide. It discovers, develops, manufactures, and markets pharmaceutical and biological prescription drugs to treat oncology, immuno-oncology, neurology, immunology, fertility, and endocrinology, as well as general medicines for diabetes, cardiovascular, thyroid, and other diseases. The company also provides life science products and services, including research, process, and applied solution.
MERCK Kommanditgesellschaft auf Aktien Fundamentals Summary
|MRK fundamental statistics|
Is MRK overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|MRK income statement (TTM)|
|Cost of Revenue||€7.13b|
Last Reported Earnings
Sep 30, 2021
Next Earnings Date
Mar 03, 2022
|Earnings per share (EPS)||6.18|
|Net Profit Margin||14.10%|
How did MRK perform over the long term?See historical performance and comparison
0.7%Current Dividend Yield
Is MERCK Kommanditgesellschaft auf Aktien undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: MRK (€193.85) is trading below our estimate of fair value (€323.03)
Significantly Below Fair Value: MRK is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: MRK is poor value based on its PE Ratio (31.3x) compared to the European Pharmaceuticals industry average (26.6x).
PE vs Market: MRK is poor value based on its PE Ratio (31.3x) compared to the German market (21.4x).
Price to Earnings Growth Ratio
PEG Ratio: MRK is poor value based on its PEG Ratio (3.7x)
Price to Book Ratio
PB vs Industry: MRK is overvalued based on its PB Ratio (4.1x) compared to the DE Pharmaceuticals industry average (3.8x).
How is MERCK Kommanditgesellschaft auf Aktien forecast to perform in the next 1 to 3 years based on estimates from 19 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: MRK's forecast earnings growth (8.5% per year) is above the savings rate (-0.01%).
Earnings vs Market: MRK's earnings (8.5% per year) are forecast to grow slower than the German market (10.4% per year).
High Growth Earnings: MRK's earnings are forecast to grow, but not significantly.
Revenue vs Market: MRK's revenue (6.1% per year) is forecast to grow faster than the German market (5.6% per year).
High Growth Revenue: MRK's revenue (6.1% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: MRK's Return on Equity is forecast to be low in 3 years time (17.2%).
How has MERCK Kommanditgesellschaft auf Aktien performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: MRK has high quality earnings.
Growing Profit Margin: MRK's current net profit margins (14.1%) are higher than last year (10.9%).
Past Earnings Growth Analysis
Earnings Trend: MRK's earnings have grown by 5.2% per year over the past 5 years.
Accelerating Growth: MRK's earnings growth over the past year (42.7%) exceeds its 5-year average (5.2% per year).
Earnings vs Industry: MRK earnings growth over the past year (42.7%) exceeded the Pharmaceuticals industry 11.9%.
Return on Equity
High ROE: MRK's Return on Equity (13.1%) is considered low.
How is MERCK Kommanditgesellschaft auf Aktien's financial position?
Financial Position Analysis
Short Term Liabilities: MRK's short term assets (€10.3B) exceed its short term liabilities (€9.8B).
Long Term Liabilities: MRK's short term assets (€10.3B) do not cover its long term liabilities (€13.4B).
Debt to Equity History and Analysis
Debt Level: MRK's net debt to equity ratio (43%) is considered high.
Reducing Debt: MRK's debt to equity ratio has reduced from 97% to 51% over the past 5 years.
Debt Coverage: MRK's debt is well covered by operating cash flow (46%).
Interest Coverage: MRK's interest payments on its debt are well covered by EBIT (19.7x coverage).
What is MERCK Kommanditgesellschaft auf Aktien current dividend yield, its reliability and sustainability?
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: MRK's dividend (0.72%) isn’t notable compared to the bottom 25% of dividend payers in the German market (1.02%).
High Dividend: MRK's dividend (0.72%) is low compared to the top 25% of dividend payers in the German market (3.34%).
Stability and Growth of Payments
Stable Dividend: MRK's dividends per share have been stable in the past 10 years.
Growing Dividend: MRK's dividend payments have increased over the past 10 years.
Current Payout to Shareholders
Dividend Coverage: With its low payout ratio (22.7%), MRK's dividend payments are well covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: MRK's dividends in 3 years are forecast to be well covered by earnings (17.9% payout ratio).
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Belen Garijo Lopez (61 yo)
Ms. Belen Garijo Lopez, M.D., serves as Chair of Executive Board and Chief Executive Officer at MERCK Kommanditgesellschaft auf Aktien since May 1, 2021 and served as Vice Chairman of the Executive Board a...
CEO Compensation Analysis
Compensation vs Market: Belen's total compensation ($USD7.67M) is above average for companies of similar size in the German market ($USD5.11M).
Compensation vs Earnings: Belen's compensation has been consistent with company performance over the past year.
Experienced Management: MRK's management team is seasoned and experienced (7 years average tenure).
Experienced Board: MRK's board of directors are considered experienced (3.9 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
MERCK Kommanditgesellschaft auf Aktien's employee growth, exchange listings and data sources
- Name: MERCK Kommanditgesellschaft auf Aktien
- Ticker: MRK
- Exchange: XTRA
- Founded: 1668
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: €84.282b
- Shares outstanding: 434.78m
- Website: https://www.merckgroup.com
Number of Employees
- MERCK Kommanditgesellschaft auf Aktien
- Frankfurter Strasse 250
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/01/17 22:58|
|End of Day Share Price||2022/01/17 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.